Belatacept conversion in an HIV‐positive kidney transplant recipient following anti‐thymocyte globulin induction

Herein, we describe a case of early belatacept conversion in a human immunodeficiency virus (HIV)‐positive kidney transplant recipient in an effort to improve suboptimal graft function and avoid drug interactions following anti‐thymocyte globulin (ATG) administration. We observed improvement in rena...

Full description

Saved in:
Bibliographic Details
Published in:Transplant infectious disease 2017-10, Vol.19 (5), p.n/a
Main Authors: Kuten, Samantha A., Patel, Samir J., Baru, Ashvin, Gaber, A. Osama, Crutchley, Rustin D., Ramanathan, Venkataraman, Knight, Richard J.
Format: Article
Language:English
Subjects:
Abatacept - pharmacology
Anti-HIV Agents - administration & dosage
Anti-HIV Agents - therapeutic use
Antibodies
Antilymphocyte Serum - pharmacology
Antiretroviral drugs
belatacept
Conversion
Globulins
HIV
HIV Infections - complications
HIV Infections - drug therapy
Human immunodeficiency virus
Humans
Immunosuppressive Agents - pharmacology
Kidney Transplantation
Kidney transplants
Male
Middle Aged
Renal function
Thymocytes
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Herein, we describe a case of early belatacept conversion in a human immunodeficiency virus (HIV)‐positive kidney transplant recipient in an effort to improve suboptimal graft function and avoid drug interactions following anti‐thymocyte globulin (ATG) administration. We observed improvement in renal function without HIV disease progression or opportunistic infections. Donor‐specific antibodies appeared shortly after conversion but cleared without intervention. This case highlights belatacept as a means to improve renal function and avoid significant drug interactions even following ATG induction.
ISSN:1398-2273
1399-3062
DOI:10.1111/tid.12748